187 related articles for article (PubMed ID: 11284774)
1. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Cornillie F; Shealy D; D'Haens G; Geboes K; Van Assche G; Ceuppens J; Wagner C; Schaible T; Plevy SE; Targan SR; Rutgeerts P
Aliment Pharmacol Ther; 2001 Apr; 15(4):463-73. PubMed ID: 11284774
[TBL] [Abstract][Full Text] [Related]
2. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
[TBL] [Abstract][Full Text] [Related]
3. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
[TBL] [Abstract][Full Text] [Related]
4. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
5. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
[TBL] [Abstract][Full Text] [Related]
7. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
Ferkolj I; Ihan A; Markovic S; Veceric Z; Pohar M
J Gastrointestin Liver Dis; 2006 Sep; 15(3):231-5. PubMed ID: 17013447
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
9. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies.
D'Alessandria C; Malviya G; Viscido A; Aratari A; Maccioni F; Amato A; Scopinaro F; Caprilli R; Signore A
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):334-42. PubMed ID: 17464276
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment.
Guidi L; Costanzo M; Ciarniello M; De Vitis I; Pioli C; Gatta L; Pace L; Tricerri A; Bartoloni C; Coppola L; Balistreri P; Doria G; Fedeli G; Gasbarrini GB
Int J Immunopathol Pharmacol; 2005; 18(1):155-64. PubMed ID: 15698520
[TBL] [Abstract][Full Text] [Related]
11. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
12. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
13. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.
Plevy SE; Landers CJ; Prehn J; Carramanzana NM; Deem RL; Shealy D; Targan SR
J Immunol; 1997 Dec; 159(12):6276-82. PubMed ID: 9550432
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Rutgeerts P; Feagan BG; Lichtenstein GR; Mayer LF; Schreiber S; Colombel JF; Rachmilewitz D; Wolf DC; Olson A; Bao W; Hanauer SB
Gastroenterology; 2004 Feb; 126(2):402-13. PubMed ID: 14762776
[TBL] [Abstract][Full Text] [Related]
16. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
17. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.
van Balkom BP; Schoon EJ; Stockbrügger RW; Wolters FL; van Hogezand RA; van Deventer SJ; Oldenburg B; van Dullemen HM; Russel MG
Aliment Pharmacol Ther; 2002 Jun; 16(6):1101-7. PubMed ID: 12030951
[TBL] [Abstract][Full Text] [Related]
18. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.
Kirman I; Whelan RL; Nielsen OH
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):639-41. PubMed ID: 15201575
[TBL] [Abstract][Full Text] [Related]
19. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohn's disease.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Sterzynska K; Iwanik K; Majewski P; Zabel M; Linke K
Folia Histochem Cytobiol; 2013; 51(3):239-43. PubMed ID: 24203631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
